This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.
1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
MM - 1660
Multiple Myeloma (MM)
Background
Renal dysfunction is common in multiple myeloma (MM) and often complicates treatment decisions. Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed outcomes in relapsed/refractory MM, patients with clinically significant chronic kidney disease (CKD) have been underrepresented in pivotal trials due to renal eligibility criteria. As a result, the real-world safety of CAR-T therapy in patients with MM who have CKD remains unclear. We evaluated outcomes after CAR-T therapy among patients with MM and concomitant CKD stage ≥3a, compared with matched patients without CKD stage ≥3a.
Methods
We performed a retrospective propensity score–matched cohort study using the TriNetX database, including patients with MM treated with CAR-T therapy who had preexisting CKD stage ≥3a (n=269) versus control patients without CKD stage ≥3a (n=1850) from 2021 to 2023. Propensity score matching (1:1 ratio) was performed using a greedy nearest-neighbor method with a caliper of 0.1 pooled SD, adjusting for demographics, MM-directed therapy, comorbidities, laboratory values, and medications. Primary outcomes were all-cause mortality, ICANS, and cytokine release syndrome (CRS). Secondary outcomes included hospitalizations, ICU admissions, and acute kidney injury (AKI). Odds ratios (ORs) with 95% confidence intervals (CIs) over 3 years were calculated.
Results
After matching, 89 pairs were analyzed. Mean age was 68.7±8.6 years in the CKD stage ≥3a group and 63.9±9.0 years in the controls; 36% of patients were female in both groups. CKD stage ≥3a was not associated with significantly different odds of all-cause mortality (OR, 1.157; 95% CI, 0.547–2.445; P=0.703), ICANS (OR, 1.380; 95% CI, 0.626–3.044; P=0.423), CRS (OR, 0.729; 95% CI, 0.405–1.315; P=0.294), hospitalization (OR, 1.000; 95% CI, 0.456–2.192; P=1.000), or ICU admission (OR, 1.301; 95% CI, 0.571–2.963; P=0.531). However, CKD stage ≥3a was associated with significantly higher odds of AKI after CAR-T therapy (OR, 1.861; 95% CI, 1.010–3.430; P=0.046).
Conclusion
In this real-world matched cohort, CKD stage ≥3a was not associated with increased mortality or immune-mediated toxicities after CAR-T therapy in MM. Notwithstanding the limited sample size and paucity of granular clinical context pertaining to patient/disease characteristics and therapeutic nuances, these findings compel the exploration of liberalizing renal inclusion criteria among CAR-T therapy prospects with moderate-to-severe CKD.
ICANS: immune effector cell–associated neurotoxicity syndrome, ICU: intensive care unit, SD: standard deviation
MM, chronic kidney disease, CAR-T therapy, cytokine release syndrome, acute kidney injury, propensity score matching